GLP-1 Drugs: Weight Regain After Stopping Semaglutide & Tirzepatide
The initial excitement surrounding GLP-1 receptor agonists like semaglutide (Ozempic/Wegovy) and tirzepatide (Mounjaro/Zepbound) for weight loss and type 2 diabetes has naturally led to questions about what happens when people stop taking these medications. A recent analysis from the Cleveland Clinic, encompassing data from nearly 8,000 patients, offers reassuring, though nuanced, insights. The study suggests that, in real-world clinical practice, discontinuing these drugs doesn’t necessarily lead to substantial weight regain for many individuals, a finding that differs from the more pronounced rebound observed in tightly controlled clinical trials.
Beyond the Trials: Real-World Outcomes
Earlier randomized clinical trials indicated that individuals who ceased using semaglutide or tirzepatide typically regained more than half of their lost weight within a year. However, the Cleveland Clinic study, published in Diabetes, Obesity and Metabolism, paints a more complex picture. Researchers found that many patients who stopped treatment either restarted the medication or transitioned to alternative weight management strategies, mitigating the extent of weight regain. This highlights a crucial difference between the artificial conditions of a clinical trial and the adaptability of treatment in everyday healthcare settings. Cleveland Clinic News Release
The retrospective cohort study included 7,938 adults with overweight or obesity in Ohio and Florida who had initiated injectable semaglutide or tirzepatide for either obesity or type 2 diabetes, and then discontinued utilize within a three-to-12-month period. Researchers then tracked subsequent treatment choices and weight changes over time.
Weight Regain: A Matter of Degrees
The data revealed varying outcomes depending on the initial reason for treatment. Patients initially treated for obesity lost an average of 8.4% of their body weight before stopping the medication and then regained only 0.5% over the following year. Those treated for type 2 diabetes experienced a loss of 4.4% before discontinuation, followed by a further loss of 1.3% during the year after stopping. While some weight regain is inevitable for many, the average increases were considerably less than those seen in the earlier clinical trials.
However, averages can be misleading. The study too showed significant individual variation. Among those treated for obesity, 55% gained weight after stopping, while 45% either continued to lose weight or maintained their weight. In the diabetes group, 44% gained weight, while 56% maintained or continued to lose weight. This underscores the importance of individualized care and ongoing support.
Why People Stop, and What Happens Next
Previous research from the same Cleveland Clinic team identified two primary reasons for discontinuing GLP-1 medications: cost and lack of insurance coverage, and the experience of side effects. Financial barriers proved to be the most common obstacle. Diabetes.co.uk
Interestingly, patients using the drugs for type 2 diabetes were more likely to restart treatment compared to those using them for obesity. This difference appears to be linked to more consistent insurance coverage for diabetes prescriptions. The study also revealed that within a year of stopping their initial GLP-1 medication, a substantial number of patients pursued alternative weight management strategies:
- 27% switched to another medication (including older-generation obesity drugs or switching between semaglutide and tirzepatide)
- 20% restarted their original medication
- 14% continued treatment through lifestyle-focused care with professionals such as dietitians or exercise specialists
- Less than 1% underwent metabolic and bariatric surgery
The Role of Continued Care
The findings emphasize that stopping medication doesn’t necessarily signify the end of a patient’s obesity treatment journey. Many individuals actively seek alternative solutions, demonstrating a commitment to managing their weight and health. “Many patients do not give up on their obesity treatment journey, even if they require to stop their initial medication,” explained Dr. Hamlet Gasoyan, the lead researcher from Cleveland Clinic’s Center for Value-Based Care Research. MSN Health
This highlights the critical role of ongoing, individualized care for people managing obesity. Simply prescribing a medication is not enough. sustained support, whether through lifestyle interventions, alternative medications, or surgical options, is essential for long-term success.
Looking Ahead: Comparative Effectiveness
The Cleveland Clinic researchers are now planning further investigations to compare the effectiveness of different treatment options for patients who discontinue semaglutide or tirzepatide. This future work aims to provide clinicians and patients with the information needed to craft informed decisions about the best course of action, recognizing that there is no one-size-fits-all approach to obesity management. The team intends to analyze which alternative therapies yield the most favorable outcomes in terms of weight maintenance, metabolic health, and overall well-being.
this study reinforces the idea that obesity treatment is a dynamic process, requiring flexibility, adaptation, and a commitment to ongoing care. It’s not about finding a magic bullet, but about empowering individuals to navigate their health journey with the support and resources they need.